An observational study in Cardiomyopathies, Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy, sponsored by Indiana University. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Indiana University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 231 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 69 under way, 6 of them phase 3. Cardiomyopathies · United States.
Among the 231 studies in Cardiomyopathies with a site in United States, this one is the 38th largest by planned enrollment of the 97 observational ones that give a count, is one of 17 that started in 2014, is one of 98 observational ones, reaches primary completion later than 59 of the 67 other live ones, and was the 109th registered.
556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.
Browse Cardiomyopathies studies →56 of the 231 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:
Atrium Therapeutics · Sites in United States
Ages 18–65
Eidos Therapeutics, a BridgeBio company · Sites in United States, Singapore, Spain
Ages 18–80
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
Old Dominion University · Sites in United States
Ages 18–85
Lexeo Therapeutics · Sites in United States, Brazil, Canada and 6 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
231 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 32 · Phase 3 20 · Phase 4 13
First in 1996; this study’s year is marked. 17 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 200 across 264 observational studies indexed under Cardiomyopathies.
Median enrollment 42 across the 132 interventional studies, 160 across the 97 observational. Of the 139 that completed or were terminated, 65 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 231 have an industry lead sponsor. The 10 most frequent:
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
Indiana University has 1 study filed under Cardiomyopathies — fewer than ten, so there is no comparison to draw.
16 of the studies in Cardiomyopathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT04843371Tulane UniversityPPG to Predict Ejection Fraction and Other Echographic Data in the General Population | 2026-12 |
| NCT03534726University of PennsylvaniaEdema and Fibrosis CMR Imaging in Cardiomyopathy | 2026-12-31 |
| NCT03049254Mayo ClinicMayo AVC Registry and Biobank | 2027-03 |
Add all 16 to your calendar (.ics) → With an account.
Among the 231 studies in Cardiomyopathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder. This will provide the basis for future genetic counseling as well as contribute to elucidating the biology of normal and abnormal cardiac function.
Cardiomyopathy is a genetically heterogeneous heart muscle disorder that results in ventricular dysfunction. While significant progress has been made in identifying the genetic basis of cardiomyopathy in adults, molecular diagnosis in children has proven more challenging and current algorithms do not incorporate mutation analysis in the clinical protocol. However, recent studies indicate that cardiomyopathy outcomes in children are origin specific, highlighting the importance of precise diagnosis. The goal of this study is to identify the genetic causes of pediatric cardiomyopathy. Rapid, comprehensive and cost-effective detection of genetic causes of cardiomyopathy will aid management and development of novel treatment strategies.
Families affected by cardiomyopathy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
participants with cardiomyopathy
Family members of participants with cardiomyopathy (can be affected or unaffected)
Elucidate the molecular genetics of cardiomyopathy
Time frame: 7 years
The record gives a start of Apr 2014, a primary completion of Dec 2030 and a completion of Dec 2030. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.